Trial Profile
To compare the survival benefit of microwave ablation plus recombinant human Endostatin (Endostar) with microwave ablation alone in patients with inoperable stage I non small cell lung cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Jun 2018
Price :
$35
*
At a glance
- Drugs Endostatin (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 05 Jun 2018 Primary endpoint (Overall Survival) has not been met, according to results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 07 Nov 2017 New trial record